DNMT3B and breast carcinoma: -Acted as a promising inhibitor that targets ABL1, DNMT3B, and MLH1 due to the similarity of binding properties with its native ligand-Hesperetin + the erbB receptor inhibitors (monoclonal antibody and tyrosine kinase inhibitor) targeted the same mRNA expression⇒ Combinatorial therapy with hesperetin targeting ABL1, DNMT3B,and MLH1 may be effective in circumventing chemoresistance in breast cancer